% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Uhl:127660,
      author       = {M. Uhl and T. Welzel and A. Jensen and M. Ellerbrock and T.
                      Haberer and O. Jäkel$^*$ and K. Herfarth and J. Debus$^*$},
      title        = {{C}arbon ion beam treatment in patients with primary and
                      recurrent sacrococcygeal chordoma.},
      journal      = {Strahlentherapie und Onkologie},
      volume       = {191},
      number       = {7},
      issn         = {0179-7158},
      address      = {Heidelberg},
      publisher    = {Springer51814},
      reportid     = {DKFZ-2017-03683},
      pages        = {597-603},
      year         = {2015},
      abstract     = {The purpose of this work was to evaluate the results of
                      high-dose radiation treatment using carbon ion therapy,
                      alone or combined with intensity-modulated radiation
                      treatment (IMRT), in patients with sacral chordoma.Between
                      2009 and 2012, 56 patients with sacral chordoma were
                      treated in our center. The tumor was located above S3 in
                      33 patients and in S3 or below in 23 patients. In all,
                      41 patients received radiation therapy for the primary
                      tumor, while 15 patients were treated for the recurrent
                      tumor. Toxicity was measured using NCI CTCAE v.4.03. Local
                      control (LC) and overall survival (OS) were evaluated with
                      the Kaplan-Meier method.A total of 23 patients were
                      irradiated with carbon ions in combination with photon IMRT,
                      while 33 received carbon ion therapy only. Forty-three
                      patients had a macroscopic tumor at treatment start with a
                      median tumor size (GTV) of 244 ml (range 5-1188 ml). The
                      median total dose was 66 Gy (range 60-74 Gy; RBE). After a
                      median follow-up time of 25 months, the 2- and 3-year local
                      control probability was $76 \%$ and $53 \%,$
                      respectively. The overall survival rate was $100 \%.$
                      Treatment for primary tumor and male patients resulted in
                      significant better local control. No higher toxicity
                      occurred within the follow-up time.High-dose photon/carbon
                      ion beam radiation therapy is safe and, especially for
                      primary sacral chordomas, highly effective. A randomized
                      trial is required to evaluate the role of primary definitive
                      hypofractionated particle therapy compared with surgery with
                      or without adjuvant radiotherapy.},
      cin          = {E040 / E050 / L101},
      ddc          = {610},
      cid          = {I:(DE-He78)E040-20160331 / I:(DE-He78)E050-20160331 /
                      I:(DE-He78)L101-20160331},
      pnm          = {315 - Imaging and radiooncology (POF3-315)},
      pid          = {G:(DE-HGF)POF3-315},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:25737378},
      doi          = {10.1007/s00066-015-0825-3},
      url          = {https://inrepo02.dkfz.de/record/127660},
}